Bio-Rad Laboratories, Inc. (BIO.B)

Market Cap	7.55B +6.3%
Revenue (ttm)	2.58B +0.7%
Net Income	759.90M
EPS	27.85
Shares Out	26.99M
PE Ratio	9.93
Forward PE	27.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Open	n/a
Previous Close	278.25
Day's Range	n/a
52-Week Range	225.29 - 321.12
Beta	1.20
Analysts	Strong Buy
Price Target	358.50 (+28.84%)
Earnings Date	Apr 30, 2026

About BIO.B

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 7,450
• Stock Exchange: NYSE
• Ticker Symbol: BIO.B
• Website: https://www.bio-rad.com

Analyst Summary

According to 4 analysts, the average rating for BIO.B stock is "Strong Buy." The 12-month stock price target is $358.5, which is an increase of 28.84% from the latest price.

Price Target

$358.5

(28.84% upside)

Analyst Consensus: Strong Buy